Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

RANDOMIZED PHASE II TRIAL OF PEMBROLIZUMAB AND RADIATION VS. RADIATION AND CONCURRENT CHEMOTHERAPY FOR HIGH-GRADE T1 BLADDER CANCER (PARRC TRIAL)

Intervention/treatment:
KEYTRUDA (PEMBROLIZUMAB)
Medical condition:
BLADDER CANCER
Protocol code:
NRG-GU014
Control number:
295991
Status:
Recruiting
Approved:
April 16, 2025
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT06770582
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
NRG ONCOLOGY

Locations

Quebec

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Québec, Quebec, G1R 2J6
RECRUITING
Name
Site Public Contact
Role
CONTACT
Name
Eric Vigneault
Role
PRINCIPAL_INVESTIGATOR
The Research Institute of the McGill University Health Centre (MUHC)
Montreal, Quebec, H3H 2R9
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
514-934-1934
Extension 48354
Name
Fabio L. Cury
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?